SB-269970 hydrochloride is a selective 5-HT7 receptor antagonist (pKi = 8.3) with over 50-fold selectivity over other receptors. It exhibits anxiolytic-like effects in rat Vogel conflict test, elevated plus maze, and mouse four-plate test at doses of 0.5–1 mg/kg. It demonstrates antidepressant-like activity in mouse forced swim test and tail suspension test at doses of 5–10 mg/kg. SB-269970 reverses amphetamine-induced hyperlocomotion and prepulse inhibition (PPI) deficits in wild-type mice, but not in 5-HT7 receptor knockout mice. It also attenuates MK-801-induced deficits and normalizes MK-801-induced glutamate release without affecting cortical dopamine release. Additionally, it shows anti-conflict effects at doses of 0.3–3 μg and significant anti-immobility effects compared to imipramine (0.1 μg) at 3–10 μg. SB-269970 blocks the effects of amphetamine (25–27% reduction at 10–30 mg/kg) and ketamine (30–38% blockade at 10–30 mg/kg), but does not affect scopolamine-induced deficits.